Universal Influenza
Vaccines Forecast
Seasonal influenza still kills an estimated 290,000 to 650,000 people worldwide every year, and current vaccines must be reformulated annually just to keep pace with a fast-mutating virus. A universal, or broadly-protective, influenza vaccine would instead target the parts of the virus that barely change, potentially ending that annual reformulation cycle and offering a first line of defence against a novel pandemic subtype, such as H5N1, before it even emerges. This is a comprehensive commercial assessment of that opportunity, updated to reflect BiondVax's M-001 Phase III setback and the NIH-led candidates that have taken up the field's lead since, drawing on VacZine Analytics' long standing, independent authority in respiratory vaccine markets.
- Format
- Executive presentation + Excel model
- Coverage
- Major Western markets
- Use cases
- Pandemic, seasonal primer, standalone
- Forecast horizon
- To 2035
- Approach
- Value ($m)/volume (mio doses) demand model
- Base edition
- 2016 edition
- Availability
- Syndicated / bespoke
seasonal influenza (WHO estimate)
2023/24 season (CDC)
1918 pandemic ("Spanish flu")
protective candidates, both NIH-led
Why seasonal vaccines fall short, and the case for a universal alternative
Influenza's dual nature, predictable seasonal drift layered over unpredictable pandemic shift, is what makes it both a routine annual vaccination target and a standing pandemic threat. This review sets out that virology, the scientific case for a broadly-protective vaccine, and the current epidemiology and pipeline picture.
Pathogen overview - Influenza A & B, and the case for broad protection
Influenza is an acute febrile respiratory illness caused by an enveloped, segmented RNA virus of the Orthomyxoviridae family. Two types, influenza A and influenza B, cause the overwhelming majority of human disease. Influenza A viruses are further classified by their two principal surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA), giving rise to subtypes such as H1N1 and H3N2. Small, gradual changes to these surface proteins, antigenic drift, occur every season and explain why a vaccine matched to last year's circulating strains offers only partial protection this year. Occasionally, a far larger change, antigenic shift, produces an entirely novel HA or NA subtype to which most of the population has no pre-existing immunity, the mechanism behind every influenza pandemic on record, including the 1918 "Spanish flu" pandemic, estimated to have caused 50 million deaths worldwide, and the 2009 H1N1 "swine flu" pandemic.
Because current seasonal vaccines are built around the variable head domain of HA, which mutates readily, they must be reformulated and re-administered every year, and their effectiveness varies considerably season to season depending on how well the selected strains match those actually in circulation. A universal, or broadly-protective, influenza vaccine instead targets the parts of the virus that change far more slowly: the conserved stalk (stem) region of HA, the M2e ectodomain, internal proteins such as nucleoprotein (NP) and matrix protein 1 (M1), or neuraminidase itself. A vaccine built around these conserved targets holds out the prospect of protection across many strains and subtypes at once, potentially removing the need for annual reformulation entirely and, just as importantly, offering a first line of defence against a novel pandemic subtype before that subtype has even emerged.
That pandemic-preparedness rationale has taken on renewed urgency amid the ongoing global spread of highly pathogenic H5N1 avian influenza, which has caused a growing number of mammalian spillover infections, including in US dairy cattle herds, since 2024. Although sustained human-to-human H5N1 transmission has not been observed, the scale of animal circulation has prompted major new pandemic-preparedness investment: the US Department of Health and Human Services and the National Institutes of Health launched the "Generation Gold Standard" universal vaccine platform, CEPI has funded Moderna's H5 candidate mRNA-1018 into Phase III testing, and governments including Australia have expanded pandemic influenza vaccine stockpiles. Each of these efforts sits on the same broadly-protective scientific rationale that this report assesses.
Underlying seasonal disease burden remains substantial even without a pandemic. The World Health Organization estimates that seasonal influenza causes 290,000 to 650,000 respiratory deaths worldwide every year, alongside a far larger, harder-to-count toll of cardiovascular and other complications. In the United States, the Centers for Disease Control and Prevention's most recent complete-season estimate, for 2023/24, put the toll at approximately 40 million symptomatic illnesses, 470,000 hospitalizations and 28,000 deaths; CDC's own modelled range across recent seasons runs even wider, from roughly 9.4 million to 51 million illnesses and 6,300 to 52,000 deaths a year, reflecting how much seasonal severity varies from year to year. However framed, this recurring burden, layered on top of pandemic risk, underpins the continuing commercial and public-health case for a broadly-protective alternative.
From one failed pivotal trial to a smaller, NIH-led field of early-stage candidates
The universal influenza vaccine field's highest-profile candidate, BiondVax's M-001, failed its pivotal Phase III trial in 2020. Six years on, leadership of the field has passed largely to NIH-led academic programmes, with no major manufacturer yet running a late-stage universal-flu-specific effort of its own.
-
BiondVax / Scinai ImmunotherapeuticsPhase III failed, October 2020M-001 Programme discontinued
BiondVax's M-001, a synthetic peptide vaccine targeting conserved HA, M1 and NP epitopes, was this field's most advanced candidate and the subject of this report's original 2016 edition. Its pivotal Phase III trial, topline results announced in October 2020, missed both primary and secondary efficacy endpoints, showing no statistically significant reduction in flu illness or severity versus placebo, despite encouraging immunogenicity data from seven earlier Phase I/II trials. BiondVax rebranded as Scinai Immunotherapeutics (NASDAQ: SCNI) in 2021 and has since pivoted entirely away from influenza vaccines, toward nanosized-antibody (NanoAb) therapeutics for inflammatory and autoimmune disease. -
NIH / NIAID Vaccine Research CenterPhase I complete, Phase II under wayH1ssF and H2ssF Ferritin nanoparticle, HA-stalk-targeted
These candidates display a stabilised HA stalk domain on a self-assembling ferritin nanoparticle, focusing the immune response on the conserved stem rather than the fast-mutating head. H1ssF, targeting group 1 subtypes such as H1 and H5, reported a well-tolerated Phase I trial with broadly cross-reactive stem-directed antibody responses and has advanced to a Phase II trial led by Duke University through NIAID's Collaborative Influenza Vaccine Innovation Centers (CIVICs) network; a companion group 2 candidate, H2ssF, is progressing in parallel, with combination "cocktail" dosing under evaluation as a route toward genuinely broad subtype coverage. -
NIH / NIAIDPhase Ib/II-III, intranasalBPL-1357 ("Generation Gold Standard") Whole-virus, BPL-inactivated
Announced jointly by HHS and NIH as a next-generation universal vaccine platform, BPL-1357 combines four low-pathogenicity avian influenza strains, chemically inactivated with beta-propiolactone while preserving whole-virus structure, to drive broad B- and T-cell responses. An intranasal formulation is now in Phase Ib and II/III testing, explicitly framed around H5N1 pandemic-preparedness as well as seasonal breadth, with FDA review targeted for 2029. -
ModernaPhase III, H5 pandemic-preparednessmRNA-1018 Strain-specific H5 candidate, not a universal vaccine
Distinct from Moderna's seasonal mRNA-1010 candidate, mRNA-1018 targets H5 avian influenza specifically rather than broad cross-subtype protection. CEPI committed up to $54 million in December 2025 to advance it into Phase III testing across the US and UK in early 2026, underscoring how H5N1 spillover concerns are now driving parallel investment in both strain-specific pandemic vaccines and genuinely universal platforms. -
OsivaxPhase IIb (Asuniva) read-out, Oct 2026 - primary endpoint missedOVX836 oligoDOM nanoparticle, T-cell/NP-targeted
A broad-spectrum influenza A candidate targeting the conserved internal nucleoprotein (NP) antigen via Osivax's self-assembling oligoDOM™ nanoparticle platform, driving T-cell responses alongside conventional antibody responses. OVX836 has now been tested in over 4,000 participants across seven clinical trials, including the Phase IIb Asuniva efficacy trial, which completed enrolment in December 2025, and is backed by a $19.5 million BARDA award (August 2025) for pandemic- and seasonal-preparedness development. In August 2026, Osivax entered a strategic collaboration with South Korea's GC Biopharma to combine OVX836 with GC Biopharma's WHO-prequalified GC FLU vaccine into a single-injection, next-generation influenza vaccine intended to pair OVX836's broad T-cell protection with GC FLU's HA-antibody response; Osivax leads global development and commercialisation outside Korea and Japan, while GC Biopharma retains Korean rights, supplies GC FLU and receives royalties. Topline Phase IIb Asuniva results, reported 15 October 2026 (2,850 healthy adults, single 480µg IM dose vs placebo; NCT05569239), missed the trial's pre-specified 50% vaccine-efficacy primary endpoint, recording a 24% point estimate against influenza-like illness that Osivax describes as not statistically significant, alongside secondary-endpoint point estimates of 27% against A/H3N2 and 25% against A/H1N1pdm09; the company called this the first consistent efficacy signal for a monovalent NP-based influenza vaccine across both major influenza A subtypes in a field efficacy trial, and says it will now pursue OVX836 primarily as a T-cell-based complement delivered alongside conventional HA-antibody vaccines, via the GC Biopharma tie-up and a second, undisclosed combination partner, rather than as a stand-alone broadly-protective vaccine. -
Sanofi & GSKNo dedicated late-stage programmeManufacturer pipelines
Neither Sanofi nor GSK currently runs a dedicated, late-stage universal-flu-specific programme; Sanofi confirmed in 2025 that it had deprioritised its own mRNA-based seasonal flu effort. This leaves the field's clinical-stage leadership concentrated in NIH-led academic programmes rather than major-manufacturer pipelines, a structural feature this report's competitive assessment addresses directly. -
Academic & biotech researchPreclinical / early Phase IChimeric HA, neuraminidase- and T-cell-based approaches
A broader academic and biotech literature continues to test chimeric haemagglutinin (cHA) constructs, neuraminidase-focused antigens, and internal-antigen, T-cell-directed designs (targeting NP and M1) for cross-strain breadth. These approaches remain preclinical or early Phase I, and published data through 2025/26 continue to demonstrate proof-of-concept immunogenicity rather than clinical efficacy.
Universal influenza vaccine development remains a scientifically difficult, largely early-stage field, six years after its highest-profile candidate failed its pivotal trial. Leadership has passed from a single commercial developer to a smaller set of NIH-led academic programmes, H1ssF/H2ssF and BPL-1357 chief among them, both still in Phase I to Phase III testing rather than commercial launch. At the same time, H5N1 avian influenza's continuing mammalian spread has sharply increased pandemic-preparedness funding and urgency behind exactly this class of broadly-protective vaccine. The VacZine Analytics model quantifies the commercial opportunity this creates across pandemic, seasonal-primer and standalone use cases, under multiple pipeline-progression scenarios to 2035.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report spanning disease burden, target product profile design, the R&D competitive landscape and scenario-based demand forecasting across major Western markets to 2035.
Value ($m)/volume (mio doses) demand modelling to 2035 across major Western markets for pandemic, seasonal-primer and standalone use cases.
Full review of BiondVax's M-001 setback, the NIH-led H1ssF/H2ssF and BPL-1357 programmes, and the wider preclinical landscape.
Ideal target product profile and clinical development pathway assessment spanning pandemic, seasonal-primer and standalone commercial segments.
Volume and value forecasts to 2035 reflecting alternative pipeline-progression and launch-timing scenarios.
Full review of seasonal influenza's global burden, pandemic history and current H5N1 pandemic-preparedness context.
Designed as an ideal tool to aid early-stage decision making in universal influenza vaccine development, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the segment and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Segment | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Pandemic preparedness use case | Major Western markets | General adult & at-risk | Pre-clinical / early-phase | Modelled |
| Seasonal-primer use case | Major Western markets | Paediatric & adult | Pre-clinical / early-phase | Modelled |
| Standalone universal vaccine | Major Western markets | General adult | Pre-clinical / early-phase | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the universal influenza vaccine opportunity.
- Executive presentation - virology, global burden, target product profile across use cases and full competitive environment review
- MS-Excel value/volume forecast model - demand outputs to 2035 across pandemic, seasonal-primer and standalone segments
- Major Western markets coverage - modelled individually and in aggregate
- Competitor intelligence - BiondVax's M-001 setback, NIH's H1ssF/H2ssF and BPL-1357 programmes, and the wider early-stage pipeline
- Updated epidemiology module - current WHO/CDC burden data alongside H5N1 pandemic-preparedness context
- Early decision-making support - target product profile and market entrance strategy guidance for early-stage universal-flu vaccine planning
Built for organisations evaluating the universal influenza vaccine opportunity
Most valuable to teams assessing the universal influenza vaccine market against their own pipeline, BD ambitions or investment thesis, now that leadership has moved to a smaller set of NIH-led candidates.
Vaccine developers
Positioning, target product profile and commercial feasibility assessment for universal-flu candidates at any stage, from preclinical through Phase III.
Corporate strategy & BD
Assess a technically difficult but strategically important category, informed by one high-profile Phase III failure and the NIH-led programmes that have followed it.
Investors & analysts
Independent assessment of pipeline risk and commercial upside across BiondVax/Scinai's pivot and the NIH-led candidates now advancing in its place.
Public health & pandemic-preparedness programmes
Demand modelling to support pandemic-preparedness planning against the backdrop of ongoing H5N1 avian influenza spread.
Researchers & academia
Comprehensive epidemiology and R&D landscape for grant, translational and pandemic-preparedness planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across pandemic, seasonal-primer and standalone commercial segments.
VacZine Analytics has long standing expertise in respiratory diseases, tracking the universal influenza vaccine opportunity continuously since this report's original 2016 edition, through BiondVax's M-001 setback and into the smaller, NIH-led field that has emerged since. This is a genuinely comprehensive analysis with a wide market focus across major Western economies, and it has been well received by clients for the depth of its target product profile and clinical development review across pandemic, seasonal-primer and standalone use cases. Few groups have followed this technically difficult, historically volatile market as closely, and that recognised, independent expertise underpins everything in the analysis.
This report was last published in 2016. A refresh would incorporate BiondVax's Phase III failure and subsequent pivot to Scinai Immunotherapeutics, the NIH-led H1ssF/H2ssF and BPL-1357 programmes now leading the field, current WHO/CDC burden data, and the H5N1 pandemic-preparedness context now driving renewed investment in broadly-protective vaccines. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc universal influenza vaccine analysis, a briefing call is included on request.